September 1, 2021 7:32am
Lighten some “loads’, I’m on the lookout for a correction in September
Pre-open indications: SELLs into Strength: 3; SELL: 2; Maintain SELL: 1
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.
Never leave an investor uninformed!
Dow futures are UP +0.29% (+104 points), S&P futures are UP +0.33% ( +15 point) and NASDAQ futures are UP +0.20% (+32 points)
U.S. stock futures were higher in early morning trading on Wednesday,
European stocks advanced after euro zone inflation data on Tuesday rattled market sentiment,
Asia-Pacific stocks were mostly higher, despite a private survey showing shrinking Chinese factory activity in August.
Data Docket: The ADP National Employment report will be released at 8:15 a.m. ET and is expected to show the addition of 600,000 private sector jobs in August.
The major averages all finished higher for the month of August, the S&P 500 rose +2.9%, the Nasdaq gained about +4% and while the Dow lagged only +1.2%.
September is historically the worst month of the year for stocks,” said LPL Financial Chief Market Strategist Ryan Detrick. “Even last year, in the face of a huge rally off the March 2020 lows, we saw a nearly 10% correction in the middle of September.”
If you didn’t know what happen at Tuesday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:
- Tuesday’s evening’s recap: “August floats bye” … https://www.regmedinvestors.com/articles/12074
- The Nasdaq closed DOWN -6.65 points (-0.04%);
- The IBB closed up +0.17% and XBI closed up +0.92%;
- Sector volume was LOW with 7 of the 27-upside having higher than the 3-month average volume with very LOW volume of 3 of 7-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was up +0.29 points or +1.79% at 16.48;
- Tuesday’s percentage (%) of the 27-upside were +0.07% (BLFS) to +4.16% (NTLA) while the 7-downside -0.75% (VSTM) to -11.58% (BSTG);
- September, session 1
- August - 12 positive and 10 negative close
- July: 6 positives, 1 holiday and 15 negative closes
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542 … to date:
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with the “pump/promote”?
Biostage (BSTG) closed down -$0.44 to $3.36 with 11,564 shares traded after Monday’s +$0.75 to $3.80 with 25,607 shares traded after Friday’s +$0.45 to $3.05 with 19,982 share traded, Thursday’s +$0.39 with 3,137 shares traded, Wednesday’s +$0.16 with 18,472 shares traded and last Tuesday’s +$0.28 with 10,590 shares traded and the previous Monday’s +$0.68 to $1.89 with 38,354 shares traded.
Question#1: Being able to trade a stock doesn't mean it is worth the share price; an equity that has WHAT is BSTG’s value proposition, after all the share price pumping – NO clinical trial?
Questiob#2: WHAT is the end game of “pumping” the share price as the float is MINIMAL compared to the ever-OUTSTANDING shares? WHERE is the SEC?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
SELL into Strength:
Intellia Therapeutics (NTLA) closed up +$6.58 after Monday’s down -$6.05 with a positive +$0.79 or +0.49% pre-market indication,
CRISPR Therapeutics (CRSP) closed up +$4.24 and has a positive +0.67 or +0.54% pre-market indication,
Editas Medicine (EDIT) closed up +$1.79 and has a positive +$0.72 or +1.13% pre-market indication,
Mesoblast (MESO) closed down -$0.79 and has a negative -$0.49 or -7.50% pre-market indication,
BioLife Solutions (BLFS) closed up +$0.04 and has a negative -$0.16 or -0.27% pre-market indication,
The BOTTOM LINE: New month, and the last of Q3, a long holiday is coming in this market, some will exit early and let stocks ride
When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started
Investors should take short-term profits to cash-up for coming drifts!
Some earnings’ Reports Outstanding:
- Applied Genetic Technologies (AGTC) – 9/8 reporting, Mesoblast (MESO) – still trying to access, Pluristem (PSTI) and Pluristem (PSTI), ReNeuron (RENE.L)
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.